EDP Renováveis, through its subsidiary EDP Renovables España, has secured a 15-year Power Purchase Agreement (PPA) with Novartis, a global medicines company, to sell electricity generated by a portfolio of 63 MW of renewable energy.
The portfolio consists of a 36 MW wind farm project and a 26.8 MW solar power plant scheduled to be installed in 2022/23.
With this new deal, EDPR has already secured PPAs for projects totaling 229 MW to be constructed in Spain from 2020 to 2023.
“The announcement of this new PPA demonstrates that we keep a fast progress towards the execution of our business plan but primarily the importance of renewables as a competitive and clean source of energy for our customers across various industries.”
Rui Teixeira, interim CEO of EDP Renováveis.
“At Novartis, environmental sustainability is aligned with our purpose to reimagine medicine to improve and extend people’s lives. Energy efficiency and renewable energy solutions are the cornerstones of our strategy for reducing emissions. We are proud to be joined by EDP Renewables and other like-minded partners on our environmental sustainability journey.”
Montse Montaner, chief sustainability officer at Novartis.
